RenovoRx Inc. (NASDAQ: RNXT)
$1.26
-0.0200 ( -1.56% ) 13.1K
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Market Data
Open
$1.26
Previous close
$1.28
Volume
13.1K
Market cap
$29.94M
Day range
$1.23 - $1.31
52 week range
$0.53 - $2.35
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jun 07, 2024 |
10-q | Quarterly Reports | 56 | May 10, 2024 |
8-k | 8K-related | 16 | May 03, 2024 |
def | Proxies and info statements | 2 | Apr 30, 2024 |
8-k | 8K-related | 14 | Apr 18, 2024 |
8-k | 8K-related | 13 | Apr 16, 2024 |
8-k | 8K-related | 19 | Apr 15, 2024 |
8-k | 8K-related | 14 | Apr 09, 2024 |
10-k | Annual reports | 93 | Apr 01, 2024 |
8-k | 8K-related | 16 | Mar 14, 2024 |